1- ((3- (methylpyridin- 4- yl)methyl)- 4- (3,4,5- trifluorophenyl)pyrrolidin- 2- one

a PET tracer for imaging synaptic vesicle glycoprotein 2A; structure in first source

Also Known As:

(11C)UCB-J; (R)-1-((3-(11C)methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one; 1-((3-((11)C-methyl-(11)C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one; 11C-UCB-J

Networked: 7 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - Pyrrolidinones: 162
      - 1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one: 7
  - Pyridines: 88
    - 1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one: 7

Experts

1.	Aigbirhio, Franklin I: 2 articles (01/2022 - 01/2020)
2.	Bertoglio, Daniele: 2 articles (01/2022 - 01/2022)
3.	Fryer, Tim D: 2 articles (01/2022 - 01/2020)
4.	Holland, Negin: 2 articles (01/2022 - 01/2020)
5.	Hong, Young T: 2 articles (01/2022 - 01/2020)
6.	O'Brien, John T: 2 articles (01/2022 - 01/2020)
7.	Rowe, James B: 2 articles (01/2022 - 01/2020)
8.	Savulich, George: 2 articles (01/2022 - 01/2020)
9.	Staelens, Steven: 2 articles (01/2022 - 01/2022)
10.	Verhaeghe, Jeroen: 2 articles (01/2022 - 01/2022)

Related Diseases

1.	Disease Progression 01/01/2022 - "On clinical application, 11C-UCB-J PET imaging may have promise for SV2A measurement in patients with HD during disease progression and after disease-modifying therapeutic strategies."
2.	Alzheimer Disease (Alzheimer's Disease) 01/01/2021 - "Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease." 12/01/2019 - "Recently, we conducted 11C-UCB-J PET on patients with mild cognitive impairment or early Alzheimer disease (AD) and found a 41% decrease in specific binding in the hippocampus compared with healthy subjects. " 12/01/2019 - "In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease." 01/01/2021 - "11C-UCB-J PET imaging, targeting synaptic vesicle glycoprotein 2A (SV2A), has been shown to be a useful indicator of synaptic density in Alzheimer's disease (AD). "
3.	Tauopathies 01/01/2022 - "Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study."
4.	Contusions 01/01/2022 - "In this study, we explored the use of synaptic vesicle glycoprotein 2A (SV2A) PET imaging to detect spinal cord lesions noninvasively after SCI. Methods: Mice (n = 7) and rats (n = 8) subjected to unilateral moderate cervical (C5) contusion were euthanized 1 wk after SCI for histologic and autoradiographic (3H-labeled (4R)-1-[(3-methylpyridin-4-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one [UCB-J]) investigation of SV2A levels. "
5.	Ischemic Stroke 01/01/2022 - "Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study." 01/01/2022 - "We hypothesized that in subacute ischemic stroke loss of synaptic density can be evaluated with 11C-UCB-J PET in the ischemic tissue and that alterations in synaptic density can be present in brain regions beyond the ischemic core. " 01/01/2022 - "We recruited ischemic stroke patients to undergo 11C-UCB-J PET/MR imaging 21 ± 8 days after stroke onset to investigate regional 11C-UCB-J SUVR (standardized uptake value ratio). "

Related Drugs and Biologics

1.	Glycoproteins (Glycoprotein)
2.	Indicators and Reagents (Reagents)
3.	saracatinib